FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schenkein David P (1.22) (1.22) (1.22)							2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]									5. Relationship of Report (Check all applicable) X Director X Officer (give title below)			wner (specify		
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET							3. Date of Earliest Transaction (Month/Day/Year) 12/01/2017									Chief Executive Officer					
(Street) CAMBRIDGE MA 02139					- 4. l' -											Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)															reisui	ı					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Exe) if ar	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,				Securitie Beneficia Owned F	eneficially wned Following		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)		
Common stock 12/01/20)17			M ⁽¹⁾		6,000	A	\$0.30)25	6,000			D			
Common stock 12/01/20					2017)17			S ⁽²⁾		5,600	D	\$61.5	1 ⁽³⁾	400		D				
Common stock 12/01/20					2017)17			S ⁽²⁾		400	D	\$62.0	8(4)	4) 0		D				
Common stock														271,772				See footnote ⁽⁵⁾			
Common stock															79,082				See footnote ⁽⁶⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/i		4. Transa Code (8)		on of		6. Date Expirati (Month/	on Da	isable and ute ear)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	er							
Stock option (right to buy)	\$0.3025	12/01/2017			M ⁽¹⁾			6,000	(7)		08/12/2019	Common stock	6,000	0	\$0.00	20,65	56	D			

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$61.03 to \$61.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$62.04 to \$62.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 5. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- 6. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- 7. This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ William Cook, as Attorney in Fact for David Schenkein

12/05/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.